Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial.

@inproceedings{Sims2015PotentialPA,
  title={Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial.},
  author={Tasha Nicholle Sims and B Gao and Robert Anthony Phillips and Israel Lowy},
  year={2015}
}
638 Background: Biomarkers of resistance or susceptibility to vascular endothelial growth factor (VEGF) inhibition have not been validated. Ziv-aflibercept (ZALTRAP), a fusion protein that binds and neutralizes ligands of VEGFR1 and VEGFR2 (e.g., VEGFA, PLGF, and VEGFB), is approved for the treatment of metastatic colorectal cancer (mCRC) in combination with FOLFIRI in patients who have progressed after oxaliplatin therapy. We are currently analyzing plasma samples from VELOUR, the registration… CONTINUE READING

Similar Papers

Topics from this paper.